GSA Capital Partners LLP Boosts Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

GSA Capital Partners LLP increased its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 368.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 271,774 shares of the company’s stock after buying an additional 213,814 shares during the quarter. GSA Capital Partners LLP owned 0.22% of Mersana Therapeutics worth $514,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Los Angeles Capital Management LLC boosted its holdings in shares of Mersana Therapeutics by 8.1% in the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock worth $358,000 after buying an additional 14,240 shares during the last quarter. US Bancorp DE purchased a new position in shares of Mersana Therapeutics in the third quarter worth approximately $31,000. Exchange Traded Concepts LLC boosted its holdings in shares of Mersana Therapeutics by 95.8% in the third quarter. Exchange Traded Concepts LLC now owns 85,006 shares of the company’s stock worth $161,000 after buying an additional 41,586 shares during the last quarter. Algert Global LLC purchased a new position in shares of Mersana Therapeutics in the second quarter worth approximately $90,000. Finally, Susquehanna Fundamental Investments LLC boosted its holdings in shares of Mersana Therapeutics by 31.9% in the second quarter. Susquehanna Fundamental Investments LLC now owns 308,691 shares of the company’s stock worth $620,000 after buying an additional 74,575 shares during the last quarter. Hedge funds and other institutional investors own 93.92% of the company’s stock.

Insider Buying and Selling at Mersana Therapeutics

In related news, CEO Martin H. Jr. Huber sold 50,423 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $1.76, for a total value of $88,744.48. Following the completion of the transaction, the chief executive officer now directly owns 116,327 shares of the company’s stock, valued at approximately $204,735.52. This trade represents a 30.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 70,849 shares of company stock valued at $129,184 in the last three months. 11.80% of the stock is currently owned by corporate insiders.

Mersana Therapeutics Trading Up 5.2 %

Shares of MRSN opened at $2.22 on Wednesday. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics, Inc. has a 1 year low of $1.22 and a 1 year high of $6.28. The company has a 50 day simple moving average of $2.06 and a two-hundred day simple moving average of $2.03. The firm has a market cap of $274.24 million, a P/E ratio of -3.64 and a beta of 1.50.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The business had revenue of $12.60 million during the quarter, compared to analyst estimates of $7.53 million. During the same period last year, the firm posted ($0.35) EPS. The company’s revenue was up 63.6% on a year-over-year basis. On average, equities analysts expect that Mersana Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Robert W. Baird dropped their price objective on shares of Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Lifesci Capital upgraded shares of Mersana Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th. Finally, Citigroup initiated coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They set a “buy” rating and a $5.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $6.00.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.